| DURECT-CORPORATION |
DURECT-CORPORATION |
85%
|
e identifiable intangible assets is determined primarily using the “income approach,” which requires a forecast of the expected future cash flows (including revenue growth rates, cost of goods sold, … |
| PAYORS |
PAYORS |
85%
|
We also concentrate on managing our relationships with our payors and wholesalers |
| SHIBO-GROUP |
SHIBO-GROUP |
85%
|
ii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses a… |
| WHOLESALERS |
WHOLESALERS |
85%
|
We also concentrate on managing our relationships with our payors and wholesalers |
| WUHAN-SHIBO-ZHENMEI-TECHNOLOGY-CO-LTD |
WUHAN-SHIBO-ZHENMEI-TECHNOLOGY-CO-LTD |
85%
|
ii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses a… |
| BLCO |
Bausch + Lomb Corporation |
72%
|
Reciprocal relationship from BLCO graph: Reciprocal relationship from BHC graph: difference between the payment due and the calculated interest at the effective interest rate of the underlying carry … |
| BLCO |
Bausch + Lomb Corporation |
72%
|
difference between the payment due and the calculated interest at the effective interest rate of the underlying carry amount of the associated note. During the three months ended March 31, 2026 and 2… |
| IRIX |
IRIDEX Corporation |
72%
|
Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| LNSR |
LENSAR, Inc. |
72%
|
Reciprocal relationship from LNSR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth… |
| MNPR |
Monopar Therapeutics Inc. |
72%
|
Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities … |
| SLGL |
Sol-Gel Technologies Ltd. |
72%
|
Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cove… |
| VKTX |
Viking Therapeutics, Inc. |
72%
|
Reciprocal relationship from VKTX graph: Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX gra… |
| XENE |
Xenon Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will… |
| BAUSCH-HEALTH-AMERICAS-INC |
BAUSCH-HEALTH-AMERICAS-INC |
62%
|
difference between the payment due and the calculated interest at the effective interest rate of the underlying carry amount of the associated note. During the three months ended March 31, 2026 and 2… |
| BB-RATING-WATCH-EVOLVING-BAUSCH-HEALTH-COMPANIES |
BB-RATING-WATCH-EVOLVING-BAUSCH-HEALTH-COMPANIES |
62%
|
difference between the payment due and the calculated interest at the effective interest rate of the underlying carry amount of the associated note. During the three months ended March 31, 2026 and 2… |
| B-C-LTD |
B-C-LTD |
62%
|
difference between the payment due and the calculated interest at the effective interest rate of the underlying carry amount of the associated note. During the three months ended March 31, 2026 and 2… |
| LOMB-INCORPORATED |
LOMB-INCORPORATED |
62%
|
ts then existing credit agreement pursuant to the Fourth Amended & Restated Credit and Guaranty Agreement, as further amended by the First Incremental Amendment to the Fourth Amended & Restated Credi… |
| OCEANSIDE-PHARMACEUTICALS-INC-BAUSCH-HEALTH-US-L |
OCEANSIDE-PHARMACEUTICALS-INC-BAUSCH-HEALTH-US-L |
62%
|
ejudice. Antitrust Litigation Generic Pricing Antitrust Litigation The Company and its subsidiaries, Oceanside Pharmaceuticals, Inc., Bausch Health US, LLC (formerly Valeant Pharmaceuticals North Ame… |
| VALEANT-PHARMACEUTICALS-INTERNATIONAL-INC |
VALEANT-PHARMACEUTICALS-INTERNATIONAL-INC |
62%
|
under the terms of the ESPP, be less than 85 % of the lower of the fair market value per common share on either the grant date or the purchase date. The first offering period to purchase common share… |
| VALEANT-PHARMACEUTICALS-NORTH-AMERICA-LLC |
VALEANT-PHARMACEUTICALS-NORTH-AMERICA-LLC |
62%
|
ejudice. Antitrust Litigation Generic Pricing Antitrust Litigation The Company and its subsidiaries, Oceanside Pharmaceuticals, Inc., Bausch Health US, LLC (formerly Valeant Pharmaceuticals North Ame… |
| WHITECAP-BIOSCIENCES-LLC |
WHITECAP-BIOSCIENCES-LLC |
62%
|
sition date. Revenues and operating results associated with this acquisition during the period from December 9, 2025 through December 31, 2025 were not material. Pro forma revenues and operating resu… |
